Sitemap

Posts

Strategic Update VI
CLINUVEL Bulletin Edition 01
CLINUVEL escalates PRÉNUMBRA® to moderate/severe stroke patients
Expansion of CLINUVEL’s global porphyria programs
News Kommuniqué II
News Communiqué I – Ms Cristina Ramos
News Communiqué II
Investor Presentation – NYC Nasdaq Event
First stroke patient treated with PRÉNUMBRA® Instant
Technical note: Arterial Ischaemic Stroke (AIS)
DNA Repair data presented at American Academy of Dermatology Meeting
Statement on Silicon Valley Bank (SVB)
Proposed issue of Securities
News Communiqué I – Maestro Jaap van Zweden
Commercial Update SCENESSE®
Relief from Quarterly Reporting
CLINUVEL launches CYACÊLLE, Next Generation Solar Care
CYACÊLLE Polychromatic Solar Care – λ3
Proposed issue of Securities
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
Appendix 4D Half Yearly Report
PRÉNUMBRA® Formulation Completed For Clinical Trial Use
Chair’s Letter
Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population – Technical Note
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population
Appendix 4C & Activity Report
Technical Note: Developing a melanocortin pipeline
NEURACTHEL® manufacturing processes advance
Media release: CLINUVEL Trial Results Show Drug Reduces DNA Damage
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum – Technical Note
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum
News Kommuniqué 1
News Communiqué I
CLINUVEL Communiqué VI
Notification of cessation of securities
Jefferies London Healthcare Conference
CLINUVEL Communiqué V
Appendix 3Y – Change of Director’s Interest Notice
Appendix 4C & Activity Report
Chair’s Address
Results of Annual General Meeting 2022
CLINUVEL Pharmaceuticals Investor Briefing Melbourne
First vitiligo patient enrolled in afamelanotide monotherapy study
CLINUVEL’s Sydney Soirée 2022
CLINUVEL PHARMACEUTICALS LTD Annual General Meeting – Notice of Meeting & Explanatory Memorandum 2022
Strategic Update V
H.C. Wainwright 24th Annual Global Investment Conference
CLINUVEL confirms AGM date
CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients
CLINUVEL Kommuniqué IV
CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2022
Appendix 4G
Revenue Growth Drives CLINUVEL’s Sixth Consecutive Annual Profit
Dividend/Distribution – CUV
Appendix 4E & Annual Report
CLINUVEL Communiqué IV
Chair’s Letter
PRÉNUMBRA® for stroke
Appendix 4C & Activity Report
CLINUVEL Kommuniqué III
Change of Director’s Interest Notice
CLINUVEL Communiqué III
Change of Director’s Interest Notice
Notice of ceasing to be a substantial holder
Jeffries Healthcare Conference June 2022
H.C. Wainwright Global Investment Conference 2022
Notice of change of interests of initial substantial holder
Notice of initial substantial holder
Strategic Update IV
Change of Director’s Interest Notice
CLINUVEL progresses vitiligo treatment program
CLINUVEL progresses vitiligo study
Notification regarding unquoted securities
Positive final results in stroke
CEO letter
Appendix 4C & Activity Report
Notice of ceasing to be a substantial holder
CLINUVEL Kommuniqué II
Initial Director’s Interest Notice
Chair’s Letter
CLINUVEL appoints new Non-Executive Director
CLINUVEL Extends Employment Agreement With CEO
DNA Repair Communiqué II
CLINUVEL Communiqué II
First XP-V Patient Treated in CLINUVEL DNA Repair Study
Change of Director’s Interest Notice
ACTH Manufacturing Update
Afamelanotide in stroke (AIS) – positive preliminary results
Change of Director’s Interest Notice
CEO letter
CLINUVEL Reports Record December Half Year Operating Profit
Appendix 4D – ASX Listing Rule 4.2A.3 Half Yearly Report
Financial Results Half Year Ended, 31 December 2021
DNA Repair Communiqué I
CLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study
Appendix 4C & Activity Report
CLINUVEL Kommuniqué 1
CLINUVEL Communiqué 1
SCENESSE® continued in Germany
Change of Director’s Interest Notice
Notification of Cessation of Securities
CLINUVEL completes enrolment in world-first stroke study
CLINUVEL’S GROWTH AND EXPANSION – H.C. Wainwright Bioconnect Conference 2022
Progress of CLINUVEL’s DNA Repair Program
Chair’s Letter to Shareholders
CLINUVEL Kommuniqué VI
SCENESSE® as Vitiligo Monotherapy
Vitiligo Communiqué IV
CLINUVEL Communiqué VI
CLINUVEL Kommuniqué V
CLINUVEL Communiqué V
In memory of David Blake – London, 18 November 2021
CLINUVEL’S GROWTH AND EXPANSION – Jefferies London Healthcare Conference
Results of Annual General Meeting 2021
Chair Address
CEO’s Address – 2021 Annual General Meeting
CLINUVEL Expands Pharmaceutical Portfolio
Strategic Update III
Response to Price Query
CLINUVEL Adds ACTH to Portfolio
Appendix 4C & Activity Report
CLINUVEL Investor Webinar Released
First Patient Treated in CLINUVEL DNA Repair Study
CLINUVEL Investor webinar
Appendix 4G & Corporate Governance Statement
CLINUVEL PHARMACEUTICALS LTD 2021 Annual General Meeting – Notice of Meeting & Explanatory Memorandum
Operations Update II
Operations Update Webcast II
CLINUVEL Progresses DNA Repair Program
CLINUVEL Key Events and Announcements
CLINUVEL Confirms AGM Date
Notification regarding unquoted securities – CUV
Presentation H.C. Wainwright Global Investment Conference
CLINUVEL Kommuniqué IV
CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2021
CLINUVEL Communiqué IV
Corporate Presentation – FY2021 Results
Appendix 4E and Preliminary Financial Report
CLINUVEL Delivers Record Revenues and Profit
Dividend/Distribution – CUV
SCIENTIFIC COMMUNIQUÉ XI: Developing Novel Treatments for Arterial Ischaemic Stroke Patients
Afamelanotide well tolerated by first stroke patients
Appendix 4C & Activity Report
Insider Insights III: Willem Blijdorp – Challenges & the Future
Insider Insights II: Willem Blijdorp – CLINUVEL’s Products, People & Social Purpose
Appendix 3Y Change of Director’s Interest Notice
Insider Insights: Willem Blijdorp – Chair of The CLINUVEL Group
Appendix 3Y Change of Director’s Interest Notice
CLINUVEL Kommuniqué III
Media Release – First stroke patient treated with afamelanotide
First stroke patient treated with afamelanotide
CLINUVEL Presentation to Jefferies Healthcare Conference
CLINUVEL Communiqué III
Appendix 3Y Change of Director’s Interest Notice
Chairman’s Letter II
SCIENTIFIC COMMUNIQUÉ X: Photoprotection and the significance of Minimal Erythema Dose (MED) testing
Appendix 4C & Activity Report
Wilsons Initiates Research Coverage of CLINUVEL
CLINUVEL Strategic Update II
CLINUVEL Kommuniqué II
CLINUVEL Communiqué II
Chair’s Letter I
Media Release – CLINUVEL Expands DNA Repair Program
SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)
Investor Presentation – Daiwa Investment Conference Tokyo 2021
Appendix 3Y Change of Director’s Interest Notice
Appendix 3Y Change of Director’s Interest Notice
SCIENTIFIC COMMUNIQUÉ IX
Operations Update Webinar
CLINUVEL Reports Tenth Consecutive Half Year Net Profit
Appendix 4D Half Year Report
Financial Results Half Year Ended 31 December 2020
SCENESSE® Granted Market Access In Israel
Kommuniqué I
Appendix 4C & Activity Report
Position vacant: Web Developer
Position vacant: Copywriter
CLINUVEL Communiqué I
H.C. Wainwright Bioconnect Conference 2021
Appendix 3G
Change in substantial holding
CLINUVEL Newsletter VI
SCIENTIFIC COMMUNIQUÉ VIII
SCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED
SCIENTIFIC COMMUNIQUÉ VII
Jefferies Virtual London Healthcare Conference Presentation
Chair’s Letter To Shareholders
Commsec Executive Series interview with Dr Philippe Wolgen
Annual General Meeting Webcast
Results of Annual General Meeting
MANAGING DIRECTOR’S PRESENTATION TO CLINUVEL ANNUAL GENERAL MEETING
CHAIR’S ADDRESS TO CLINUVEL ANNUAL GENERAL MEETING
CLINUVEL Strategic Update – Extended
APPENDIX 4C AND ACTIVITY REPORT
CLINUVEL Strategic Update – Executive Summary
Afamelanotide for Acute Stroke Patients
Media Release – CLINUVEL to Trial Innovative Drug in Stroke
Media Release – TGA approves Australian drug to protect patients from light and sun
Australian TGA approves SCENESSE®
Update: SCENESSE® in DNA Repair
CLINUVEL Pharmaceuticals Limited (ASX: CUV) – Trading Halt
CLINUVEL AGM Shareholder Question Form
Further Research Coverage Initiated on CLINUVEL
Presentation – Value in the Vines Investor Conference
Appendix 4G and Corporate Governance Statement
CLINUVEL Annual General Meeting 2020
CLINUVEL Annual Report 2020
SCIENTIFIC COMMUNIQUÉ VI
CLINUVEL News & Facts site live
Kommuniqué V, 20-23 September 2020
CLINUVEL Newsletter V
CLINUVEL CONFIRMS AGM DATE
Change of Director’s Interest Notice
Media Release – First patient dosed in SCENESSE® DNA Repair Program
First patient dosed in SCENESSE® DNA Repair Program
Media Release (ASX) – CLINUVEL progresses innovative DNA Repair Program
Media Release – New drug to repair damaged skin and reduce skin cancer risk
SCENESSE® in DNA Repair
Change of Director’s Interest Notice – Appendix 3Y
Proposed issue of Securities
Opening of VALLAURIX R&D facilities in Singapore
Media Release – CLINUVEL opens VALLAURIX R&D centre in Singapore
Corporate Presentation – 2020 Full Year Results
CLINUVEL Declares Full Year Dividend
CLINUVEL Full Year Results 2020
CLINUVEL Webinar – Preliminary Financial Results
Appendix 4E and Preliminary Financial Report 2020
CLINUVEL Corporate Update
Appendix 4C – quarterly
Kommuniqué IV
CLINUVEL Newsletter
Media Release – Second Afamelanotide Formulation
PRÉNUMBRA® – New Liquid Afamelanotide Presentation
Lapse and Forfeit of Unlisted Conditional Performance Rights
Presentation Jefferies Global Healthcare Conference
Appendix 3B and Appendix 3Y Withdrawn
CLINUVEL Expands Singapore Laboratories
Request for FDA Guidance Meeting SCENESSE® in Vitiligo
Australian TGA commences SCENESSE® review
Appendix 4C
CLINUVEL Kommuniqué I
CLINUVEL Newsletter
SCENESSE® registration dossier submitted in Australia
Notice of Change of Interests of Substantial Holder
Change of Director’s Interest Notice
Lapse and Forfeit of Unlisted Conditional Performance Rights
Changes of Director’s Interest Notice
Appendix 3B
Changes in Composition to Committeess
CEO Letter
Appendix 3X
CLINUVEL Appoints Non-Executive Director
Chair’s Address to the Annual General Meeting
Results of Meeting
Managing Director’s AGM Presentation
Appendix 4C
TGA Priority Registration Pathway for SCENESSE
Letter from the Remuneration Committee Chair
CLINUVEL Chair to Retire Following FDA Approval
Appendix 4G and Corporate Governance Statement
Annual Report to shareholders
Notice of Annual General Meeting/Proxy Form
CLINUVEL Newsletter
Chair Letter to Shareholders
Audio Transcript Investor Teleconference
FDA Grants Marketing Approval For SCENESSE
Trading Halt
CLINUVEL Renews Employment Agreement With CEO
FDA Clarifies SCENESSE® PDUFA Date
CLINUVEL Confirms AGM Date
Appendix 3X
CLINUVEL Appoints New Director
SCENESSE® presented at ICPP in Milan
Appendix 3Y
CLINUVEL Notification of Dividend/Distribution
CLINUVEL Clarifies ex-Dividend Date
CLINUVEL Declares Final Dividend
Appendix 4E and Preliminary Financial Report
CLINUVEL program discussed at Light and Life 2019 Conference
CLINUVEL Newsletter – August 2019
Appendix 4C
Change in Composition of Audit & Risk Committee
CLINUVEL Newsletter – July 2019
CLINUVEL Relocates Melbourne Office
CLINUVEL INCLUDED IN S&P/ASX 200 INDEX
Presentation Jefferies Healthcare Conference
Lapse and forfeit of Unlisted Conditional Performance Rights
Media Release – US FDA review for SCENESSE® extended 3 months
US FDA extends PDUFA date for SCENESSE®
Change of Director’s Interest Notice
Becoming a substantial holder
CLINUVEL Newsletter
Appendix 4C
Chair Letter to Shareholders
Presentation Goldman Sachs Emerging Leaders Conference
CLINUVEL Hosts European EPP Clinical Expert Meetings
CLINUVEL Newsletter – March 2019
UK NICE Meeting Held
Change in substantial holding
Change in substantial holding
Change of Director’s Interest Notice x 3
Appendix 3B
Investor Briefing
Appendix 4D Half Yearly Report
CLINUVEL Vitiligo Communiqué II
CLINUVEL Newsletter – February 2019
Appendix 4C
Change of Director’s Interest Notice
CLINUVEL Newsletter – January 2019
US FDA sets PDUFA date for SCENESSE®
CLINUVEL Vitiligo Communiqué
CUV103 Singaporean Phase II vitiligo study results
CLINUVEL Newsletter – December 2018
Results of Meeting
Managing Director AGM Presentation
Chair’s Address to the Annual General Meeting
CLINUVEL Newsletter – November 2018
Appendix 4C
CLINUVEL expands Singapore laboratory facilities
Appendix 4G and Corporate Governance Statement
Notice of Annual General Meeting/Proxy Form
Appeal Upheld Against NICE Recommendation in England
Sachs 18th Biotech in Europe Forum Presentation
Chair Letter to Shareholders
Ceasing to be a substantial holder
CLINUVEL Confirms AGM Date
CLINUVEL Initiates Variegate Porphyria Proof of Concept Study
Nasdaq International Designation Virtual Investor Conference Presentation
Appendix 3B
Investor Presentation NewsMakers Conference
US FDA Update
Change in substantial holding
Notification of dividend / distribution
CLINUVEL declares first time dividend
Appendix 4E and Preliminary Financial Report
CLINUVEL Investor Summary
Appendix 4C
CLINUVEL Newsletter – July 2018
Change in substantial holding
Change in Director’s Interest Notice
Change in substantial holding
CLINUVEL COMPLETES SCENESSE® FDA FILING
Trading Halt
Appendix 3B
NICE MAINTAINS ITS POSITION NOT TO RECOMMEND SCENESSE® FOR REIMBURSEMENT
Change in substantial holding
Change in substantial holding
CLINUVEL REGULATORY UPDATE
Change in substantial holding
CLINUVEL TO TAKE 100% OWNERSHIP OF VALLAURIX
Appendix 4C
CLINUVEL Newsletter – March 2018
CLINUVEL HOLDS EUROPEAN ERYTHROPOIETIC PROTOPORPHYRIA (EPP) EXPERT MEETING
CLINUVEL sustains profitability first-half of year
CLINUVEL unveils new global positioning
CLINUVEL Newsletter – February 2018
Appendix 3X – Karen Agersborg
Appendix 4C
CLINUVEL appoints US based Director
Chair Letter to Shareholders
Preliminary recommendation by NICE not to include SCENESSE® for reimbursement by NHS England
CLINUVEL Newsletter – December 2017
Lapse and Forfeit of Unlisted Conditional Performance Rights
Appendix 3Z – Final Director’s Interest Notice
Managing Director’s AGM Presentation
Results of Meeting
Chair’s Address to the Annual General Meeting
Response to ASX Price Query
Appendix 4C
Notice of Annual General Meeting/Proxy Form
Appendix 4G
CLINUVEL Newsletter – October 2017
CLINUVEL CONFIRMS AGM DATE
ELIE ISHAG TO RETIRE FROM CLINUVEL BOARD
CLINUVEL PROVIDES UPDATE ON SCENESSE® FDA FILING
Appendix 3B
Appendix 4E – Preliminary Final Report 2016/17
Notice of change of interests of a substantial holder
Appendix 4C – Quarterly report
CLINUVEL Newsletter – July 2017
Appendix 3B
CLINUVEL Newsletter – May 2017
NICE ENGLAND UPDATE ON SCENESSE®
Appendix 4C – Quarterly report
Lapse and Forfeit of Unlisted Conditional Performance Rights
CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
Appendix 4D and Half Year Report
CLINUVEL Newsletter – February 2017
Appendix 4C – Quarterly report
Appendix 3Y
CLINUVEL Newsletter – December 2016
Appendix 3Y
Results of Meeting
Chair’s Address to the Annual General Meeting
Managing Director’s AGM Presentation
CLINUVEL agrees with FDA on New Drug Application timelines
Response to Price Query
Appendix 4C
Notice of Annual General Meeting/Proxy Form
Appendix 4G
CLINUVEL relocates Melbourne office
FDA erythropoietic protoporphyria (EPP) scientific workshop
SCENESSE® NICE ENGLAND UPDATE
FDA SCHEDULES PRE-NDA MEETING FOR SCENESSE®
Media release: FDA, CLINUVEL TO DISCUSS SCENESSE® AT PRE-NDA MEETING
CLINUVEL Confirms Date of Annual General Meeting
Chair’s Letter
Appendix 4E – Preliminary Final Report 2015/16
Lapse and Forfeit of Unlisted Conditional Performance Rights
CLINUVEL Newsletter – August 2016
Notice of Initial Substantial Holder
Appendix 3Y
Appendix 3B
CLINUVEL completes pre-clinical study of SCENESSE® as combination therapy
Appendix 4C – Q4 FY16
FDA accepts SCENESSE® clinical data package for NDA submission
FDA awards SCENESSE® Fast Track designation for treatment of EPP
CLINUVEL’s SCENESSE® launched in Europe
CLINUVEL added to Nasdaq International Designation
SCENESSE® treatment in Europe
Appendix 4C – Q3 FY16
Form 604
CLINUVEL Newsletter – April 2016
NICE Highly Specialised Technology workshop reviews SCENESSE®
s.708A Notice
Appendix 3B
Form 604
Form 604 – March 15, 2016
CLINUVEL accredits first European EPP expert centres
CLINUVEL placement of A$8.3 million completed successfully
Request for Trading Halt
Appendix 4D and Half Year Report
CLINUVEL brief on European commercialisation
SCENESSE® receives US FDA orphan designation for cutaneous porphyrias
Presentation to international porphyria patient group
Appendix 4C – Q2 FY16
Form 604
CEO Brief – January 20, 2016
Form 604

Contacts

Sitemap

Pages

Posts

Questions?

Get in touch